Truvitech's patent-pending technology uses a unique combination of biochemical profiling, cell-based screening, and machine learning to rapidly discover responsive pharmacological targets. The two key components of the platform are a specially designed chemical probe set and a unique algorithm for data analysis. The approach frequently identifies not just one, but several druggable targets. This is critical information for developing efficacious drugs, and also valuable for designing optimal drug combinations. In addition, the platform identifies biological components whose engagement must be avoided to maximize therapeutic efficacy (anti-targets). Together, these features provide an unprecedented advantage for drug discovery programs.